Wuxi Biologics (Cayman) (WXIBF) Stock Statistics & Valuation Metrics

Wuxi Biologics (Cayman) has a market cap or net worth of $26.04B. The enterprise value is $140.19B.

Market Cap

$26.04B

Enterprise Value

$140.19B

Wuxi Biologics (Cayman) has 4,117,232,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

4,117,232,000

Owned by Insiders

―

Owned by Institutions

16.85%

Wuxi Biologics (Cayman)’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 9.26%.

Return on Equity (ROE)

0.10

Return on Assets (ROA)

0.08

Return on Invested Capital (ROIC)

9.26%

Return on Capital Employed (ROCE)

0.12

Revenue Per Employee

1.48M

Profits Per Employee

333.79K

Employee Count

14,705

Asset Turnover

0.34

Inventory Turnover

8.17

The current PE Ratio of Wuxi Biologics (Cayman) is 34.90. Wuxi Biologics (Cayman)’s PEG ratio is 1.76.

PE Ratio

34.90

PS Ratio

7.29

PB Ratio

3.60

Price to FCF

38.94

Price to Operating Cash Flow

19.10

PEG Ratio

1.76

In the last 12 months, Wuxi Biologics (Cayman) had revenue of 21.79B and earned 4.91B in profits. Earnings per share was 1.16.

Revenue

21.79B

Gross Profit

10.02B

Operating Income

6.64B

Pretax Income

7.26B

Net Income

4.91B

EBITDA

8.37B

Earnings Per Share (EPS)

1.16

In the last 12 months, operating cash flow was 9.05B and capital expenditures -4.63B, giving a free cash flow of 4.42B billion.

Operating Cash Flow

9.05B

Free Cash Flow

4.42B

Free Cash Flow per Share

1.08

Wuxi Biologics (Cayman) pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

2.57%

Earnings Yield

2.90%

Beta

-0.19

52-Week Price Change

41.11%

50-Day Moving Average

6.41

200-Day Moving Average

5.13

Relative Strength Index (RSI)

48.82

Average Volume (3m)

11.84K

Wuxi Biologics (Cayman) upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).

Last Earnings Date

Aug 25, 2026

Next Earnings Date

Mar 23, 2027

Ex-Dividend Date

―

Wuxi Biologics (Cayman) as a current ratio of 3.14, with Debt / Equity ratio of 6.57%

Current Ratio

3.14

Quick Ratio

2.97

Debt to Market Cap

0.01

Net Debt to EBITDA

-0.73

Interest Coverage Ratio

47.65

In the past 12 months, Wuxi Biologics (Cayman) has paid 1.52B in taxes.

Income Tax

1.52B

Effective Tax Rate

0.21

Wuxi Biologics (Cayman) EV to EBITDA ratio is 17.50, with an EV/FCF ratio of 37.49.

EV to Sales

7.02

EV to EBITDA

17.50

EV to Free Cash Flow

37.49

EV to Operating Cash Flow

18.32

Wuxi Biologics (Cayman) has $13.04B in cash and marketable securities with $2.73B in debt, giving a net cash position of $10.31B billion.

Cash & Marketable Securities

$13.04B

Total Debt

$2.73B

Net Cash

$10.31B

Net Cash Per Share

$2.50

Tangible Book Value Per Share

$12.56

Gross margin is 47.47%, with operating margin of 32.36%, and net profit margin of 21.20%.

Gross Margin

47.47%

Operating Margin

32.36%

Pretax Margin

31.10%

Net Profit Margin

21.20%

EBITDA Margin

40.11%

EBIT Margin

32.38%

The average price target for Wuxi Biologics (Cayman) is $7.62, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$7.62

Price Target Upside

19.97% Upside

Analyst Consensus

Strong Buy

Analyst Count

14

Revenue Growth Forecast

21.58%

EPS Growth Forecast

21.59%

Smart Score

10

AI Score

―